SIL-204 Demonstrates Synergy with Chemotherapy in KRAS-Driven Pancreatic Cancer Models
核心洞察
Silexion Therapeutics (搜索)' SIL-204, a next-generation siRNA candidate, shows synergistic effects with first-line chemotherapies in preclinical models of KRAS (搜索)-mutated pancreatic cancer (搜索).
SIL-204 amplified the efficacy of chemotherapeutic agents like 5-fluorouracil, irinotecan, and gemcitabine, leading to greater reductions in cancer cell confluence.
Silexion is advancing SIL-204 with toxicology studies underway and Phase 2/3 trials planned for 2026, aiming to address a significant unmet need in KRAS (搜索)-driven cancers.
Silexion Therapeutics (搜索)' SIL-204, a next-generation siRNA candidate, has demonstrated promising synergistic effects with standard chemotherapy agents in preclinical models of pancreatic cancer (搜索) driven by KRAS (搜索) mutations. The data suggests that SIL-204 could enhance the efficacy of existing treatments for this aggressive and difficult-to-treat cancer.
Preclinical Findings
New preclinical data reveals that SIL-204, when combined with first-line chemotherapy agents such as 5-fluorouracil, irinotecan, and gemcitabine, significantly amplified the reduction in cancer cell confluence compared to chemotherapy alone in human pancreatic tumor cell models harboring KRAS (搜索) G12D mutations. These findings highlight the potential of SIL-204 to improve treatment outcomes for pancreatic cancer (搜索), where KRAS mutations are present in over 90% of cases.
SIL-204: A Next-Generation RNAi Therapeutic
Building on the foundation of its first-generation LODER™ platform, which showed improved overall survival in Phase 2 trials, Silexion's SIL-204 is designed to target a broader spectrum of KRAS (搜索) mutations. This next-generation RNAi approach aims to address the limitations of current therapies and provide a more effective treatment option for patients with KRAS-driven cancers.
Development Timeline and Financial Support
Silexion is currently conducting toxicology studies for SIL-204, with Phase 2/3 trials anticipated to begin in 2026. To support these clinical efforts, the company recently announced the pricing of a $5 million public offering. This additional capital is expected to bolster Silexion's ability to advance SIL-204 through clinical development and achieve key milestones.
Addressing Unmet Needs in KRAS-Driven Cancers
KRAS (搜索) mutations are among the most common oncogenic drivers in human cancers, contributing to aggressive tumor growth and resistance to treatment. Silexion's development of SIL-204 represents a significant step forward in addressing the unmet medical need for effective therapies targeting these mutations. The synergistic effects observed in preclinical studies suggest that SIL-204 has the potential to transform outcomes for patients with KRAS-driven pancreatic cancer (搜索) and other solid tumors.